ClinicalTrials.gg
Not yet recruitingNCT07813156LIFECOG-PDUpdated Sep 10, 2026

Idiopathic Parkinson's Disease: Interest of an Early Group-Based Cognitive Rehabilitation Program (LIFECOG-PD)

An interventional study of cognitive rehabilitation program in Parkinson Disease (PD), sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · University Hospital, Clermont-Ferrand.

Planned enrollment
18th of 23
24 · median 46
Started
2026
with 2 others
No phase
18 of 25
4 open now
Registered
25th of 25
by date

Among the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, this one is the 18th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, and was the 25th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

Current pharmacological treatments have not demonstrated significant improvement in cognitive impairment in Parkinson's disease (PD). Given the high prevalence and serious impact of cognitive impairment in PD, there is a pressing need for non-pharmacological interventions with demonstrated functional benefits. Cognitive rehabilitation is a structured program designed to help improve or compensate for patients' cognitive abilities by providing an approach tailored to each patient's individual needs and goals. Neuropsychologists from French Parkinson's Disease expert centers have developed a new cognitive rehabilitation program called LifeCOG-PD, for PD patients with a subjective cognitive complaint or a mild cognitive impairment (MCI), delivered at the hospital in seven 90-minute sessions conducted in groups of 3-4 participants. This program, combining psychoeducation, practical strategies, and personalized goal setting, aims to maintain patients' daily autonomy, enhance quality of life, and delay the cognitive impact of the disease.

By evaluating feasibility, acceptability and functional outcomes, this study will contribute critical data to inform future PD management guidelines to help support autonomy and cognitive resilience in PD.

Read the detailed description

This pilot interventional therapeutic study will aim at evaluating the feasibility and acceptability of a new cognitive rehabilitation program designed to preserve autonomy and social roles among early PD MCI patients or isolated subjective cognitive complaint.

24 patients will be enrolled in this study in 5 french centers : Clermont-Ferrand, Bordeaux, Créteil, Nancy and Strasbourg.

The inclusion period is 12 months, and each patient's participation duration is a maximum of 13 months. This study will include 10 visits at the hospital :

  • inclusion visit (during the month preceding the start of the program)
  • 7 sessions of the program (W0, W2, W4, W6, W8, W10, W112)
  • a visit at 24 weeks (3 months after the end of the program)
  • a visit at 48 weeks (9 months after the end of the program)

Patients will receive 7 sessions of 1.5 hours each at their expert centre, spaced 15 days apart, in groups of 3-4 patients. The sessions will address theoretical and practical topics such as working memory and executive functions, attention, and prospective memory in relation to their personal goals. The neuropsychologist will be blinded from the neuropsychological assessment and the functional goals.

If the patient has a caregiver (spouse or other relative), the investigator may propose them to participate in the study. Their participation will consist of completing a satisfaction questionnaire assessing the perceived benefits of the program for the patient at 3 and 9 months post-program. If they agree, the investigator will obtain their agreement to the collection and use of their data within the framework of this research.

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

Keywords

  • parkinson' s disease
  • cognitive rehabilitation program
  • subjective cognitive complaint or a mild cognitive impairment
  • functional autonomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Men or women ≥18 years old, diagnosed with idiopathic Parkinson's disease according to the official diagnostic criteria defined by the Movement Disorder Society (MDS) ;

      • Without cognitive impairment based on neuropsychological evaluation or meeting level 2 Mild Cognitive Impairment (MCI) criteria defined by the MDS, and presenting an early subjective cognitive complaint defined by a score between 1 and 8 on the Subjective Cognitive Complaints Questionnaire for Parkinson's Disease (SCCQ-PD)
      • Non-demented according to MDS criteria
      • Ability to understand the protocol;
      • Ability to provide free and ;
      • Patients covered by a social insurance system.

Exclusion criteria

Exclusion Criteria:

    • Any associated neurological disorder or active psychiatric pathology, including severe depressive episode or active psychotic episode. Participants with a Beck Depression Inventory (BDI-II) score above 21 will be excluded from the study and referred to an appropriate healthcare professional for further evaluation and follow-up as needed.

      • Patients meeting the criteria for Parkinson's disease dementia
      • Any clinical sign suggesting atypical parkinsonian syndrome (ocular motor disorder, cognitive impairment, apraxia, early falls).
      • Pregnant or breastfeeding women
      • Participants under legal protection measures such as judicial protection, deprivation of liberty, curatorship, or guardianship.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    cognitive rehabilitation program

    Patients will receive the new cognitive rehabilitation program.

    Other: cognitive rehabilitation program

Interventions

  • Othercognitive rehabilitation program

    Patients will receive the program in 7 sessions of 1.5 hours each at their expert centre, spaced 15 days apart, in groups of 3-4 patients. The sessions will address theoretical and practical topics such as working memory and executive functions, attention, and prospective memory in relation to their personal goals.

06

What researchers measure

Primary outcomes

  1. Proportion of patients completing the 7 sessions of the program

    Time frame: at the end of the program at 12 weeks

Secondary outcomes

  1. Proportion of ineligible participants after screening and inclusion

    Time frame: at inclusion visit

  2. Number of participants who withdrew until the end of the program (Dropout rates).

    Time frame: at the end of the program at 12 weeks

  3. Perceived level of interest with a satisfaction questionnaire (The Satisfaction with Therapy and Therapist Scale-Revised (STTS-R)

    Time frame: At the end the program at 12 weeks

  4. Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using qualitative questionnaire

    Time frame: et the end of the program at 12 weeks

  5. Perceived benefits of the program as reported by the participant at 3 months post treatment using qualitative questionnaire

    Time frame: at 24 weeks

  6. Perceived benefits of the program as reported by the participant at 9 months post treatment using qualitative questionnaire

    Time frame: at 48 weeks

  7. Perceived benefits of the program as reported by one of the patient's relatives at 3 months post treatment using qualitative questionnaire

    Time frame: at 24 weeks

  8. Perceived benefits of the program as reported by one of the patient's relatives at 9 months post treatment using qualitative questionnaire

    Time frame: at 48 weeks

  9. Level of achievement of individualized functional goals, assessed using GAS (treated as continuous data transformed by the zscore approach)

    Time frame: at 24 weeks

  10. Level of achievement of individualized functional goals, assessed using GAS (treated as continuous data transformed by the zscore approach)

    Time frame: at 48 weeks

  11. Functional autonomy with the Penn's Parkinson Autonomy Questionnaire-15 items (PDAQ-15)

    Time frame: at inclusion visit

  12. Functional autonomy with the Penn's Parkinson Autonomy Questionnaire-15 items (PDAQ-15)

    Time frame: at 24 weeks

  13. Functional autonomy with the Penn's Parkinson Autonomy Questionnaire-15 items (PDAQ-15)

    Time frame: at 48 weeks

  14. Global subjective cognitive complaints : Subjective Cognitive Complaints Questionnaire for Parkinson's disease (SCCQ-PD)

    Time frame: at inclusion visit

  15. Global subjective cognitive complaints : Subjective Cognitive Complaints Questionnaire for Parkinson's disease (SCCQ-PD)

    Time frame: at 24 weeks

  16. Global subjective cognitive complaints : Subjective Cognitive Complaints Questionnaire for Parkinson's disease (SCCQ-PD)

    Time frame: at 48 weeks

  17. Quality of life using the Parkinson's Disease Questionnaire (PDQ-39)

    Time frame: at inclusion visit

  18. Quality of life using the Parkinson's Disease Questionnaire (PDQ-39)

    Time frame: at 24 weeks

  19. Quality of life using the Parkinson's Disease Questionnaire (PDQ-39)

    Time frame: at 48 weeks

  20. Self-Esteem using the Rosenberg Self-Esteem Scale

    Time frame: at inclusion visit

  21. Self-Esteem using the Rosenberg Self-Esteem Scale

    Time frame: at 24 weeks

  22. Self-Esteem using the Rosenberg Self-Esteem Scale

    Time frame: at 48 weeks

  23. Depressive symptoms using the Beck Depression Inventory II (BDI-II)

    Time frame: at inclusion visit

  24. Depressive symptoms using the Beck Depression Inventory II (BDI-II)

    Time frame: at 24 weeks

  25. Depressive symptoms using the Beck Depression Inventory II (BDI-II)

    Time frame: at 48 weeks

  26. Global cognitive assessment using the Montreal Cognitive Assessment

    Time frame: at inclusion visit

  27. Global cognitive assessment using the Montreal Cognitive Assessment

    Time frame: at 48 weeks

  28. Episodic memory using the 16-items Free and Cued Selective Reminding Test

    Time frame: at inclusion visit

  29. Episodic memory using the 16-items Free and Cued Selective Reminding Test

    Time frame: at 48 weeks

  30. Episodic memory using the Brief Visuospatial Memory Test-R

    Time frame: at inclusion visit

  31. Episodic memory using brief Visuospatial Memory Test-R

    Time frame: at 48 weeks

  32. Attention using Digit Symbol Modalities test

    Time frame: at inclusion visit

  33. Attention using Digit Symbol Modalities test

    Time frame: at 48 weeks

  34. Attention using the Digit Span (Forward and Backward)

    Time frame: at inclusion visit

  35. Attention using digit Span (Forward and Backward)

    Time frame: at 48 weeks

  36. Executive functions using oral Letter-Number Sequencing task

    Time frame: at inclusion visit

  37. Executive functions using oral Letter-Number Sequencing task

    Time frame: at 48 weeks

  38. Executive functions using stroop Color and Word Test D-KEFS

    Time frame: at inclusion visit

  39. Executive functions using stroop Color and Word Test D-KEFS

    Time frame: at 48 weeks

  40. Visuo spatial treatment using the Benton Judgment of Line Orientation Test

    Time frame: at inclusion visit

  41. Visuo spatial treatment using the Benton Judgment of Line Orientation Test

    Time frame: at 48 weeks

  42. Visuo spatial treatment using the clock drawing test

    Time frame: at inclusion visit

  43. Visuo spatial treatment using the clock drawing test

    Time frame: at 48 weeks

  44. Language using the Boston Naming Test (French short form)

    Time frame: at inclusion visit

  45. Language using the Boston Naming Test (French short form)

    Time frame: at 48 weeks

  46. Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire

    at the end of the first session of the program

    Time frame: at week 0

  47. Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire

    at the end of the session 2 of the program

    Time frame: at 2 weeks

  48. Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire

    at the end of the session 3 of the program

    Time frame: at 4 weeks

  49. Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire

    at the end of the session 4 of the program

    Time frame: at 6 weeks

  50. Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire

    at the end of the session 5 of the program

    Time frame: at 8 weeks

  51. Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire

    at the end of the session 6 of the program

    Time frame: at 10 weeks

  52. Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire

    at the end of the session 7 of the program

    Time frame: at 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 10, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07813156
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Lise LACLAUTRE
Contact
promo_interne_drci@chu-clermontferrand.fr
+334.73.754.963
Tiphaine VIDAL
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion